Patient P-01483

Synthetic patientNBL-101 · Day 109 · 45–54 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Unstable

Tolerance

Improving

GI state

Favorable

Inflammatory state

Improving

Nutritional resilience

Declining

Discontinuation risk

27%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 72 AD-05 recommended — Adherence Support AD-05
Day 73 Patient accepted — Started AD-05 in the companion
Day 78 No meaningful change — Adherence Support AD-05
Day 89 Trajectory diverged from prediction — Observed response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 89.

Primary contributors, last 14 days

Treatment adherence-9
Toxicity-8
Inflammatory activity-5
Nutritional resilience-5

What helped?

Adherence Support AD-05Day 72
Result: no meaningful change

LIFE OS recommendation

No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

21.4/100

worsening · +2.7 vs previous 14 d

Toxicity

Blood

13/100

improving · -2.9 vs previous 14 d

Sleep quality

Wearable

23.4/100

worsening · -5.1 vs previous 14 d

Energy level

Daily log

4.4/10

worsening · -0.4 vs previous 14 d

Stress level

Daily log

4.4/10

worsening · +0.4 vs previous 14 d

Steps

Wearable

4,110

worsening · -279 vs previous 14 d

Adherence

Companion

79.8 %

worsening · -5.0 vs previous 14 d

This trajectory is doing well — what to keep, what to watch

Steering view →

Heading towards restoration · 67 from the failing basin, 43 from restoration.

Good elements to keep

Butyrate producers intact
hidden · steering +7.5
Adherence Support AD-05
intervention · steering +1.3

Main detractors to watch

Rapid metabolizer
hidden · steering -8
Bacteroides fragilis elevated
hidden · steering -7.4
Histamine load
perturbation · steering -3.4
Poor-sleep week
perturbation · steering -3
Histamine load
detractor · GI +2.3 next day

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+2.3detractor · 68%
Simple carbohydrates
+0.4no signal · 15%
Alcohol
-0.4no signal · 15%
Spicy / capsaicin
+0.4no signal · 15%
Dietary fat load
+0.1no signal · 15%
Insoluble fibre
+0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
Autonomic recovery ↑20
- WearableShort sleep window
Mucosal barrier integrity ↓10
- WearableSleep 5.3 h, below personal baseline

DNA

Fictional pharmacogenomic panel

CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 4.4 · butyrate capacity 48/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 57 ms
Sleep: 5.8 h
Steps: 4,833
Resting HR: 63 bpm

Daily log: GI score 21, nutritional resilience 63, adherence 80.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01313	53%	S01	BR-03	improved	32
P-01618	40%	S10	GI-04	improved	39
P-01861	39%	S12	HY-01	improved	47
P-01374	38%	S08	HY-01	improved	49
P-01320	37%	S09	HY-01	improved	38
P-01385	37%	S06	HY-01	improved	50
P-01752	37%	S20	DT-01	improved	50
P-01555	36%	S06	GI-04	improved	56
P-01346	35%	S12	DT-01	improved	52
P-01731	35%	S01	ME-01	improved	32
P-01342	34%	S11	DT-01	improved	48
P-01405	34%	S14	SC-12	improved	44